Use of fibrates in the United States and Canada

JAMA

Volumn 305, Issue 12, 2011, Pages 1217-1224

  Jackevicius, Cynthia A ^a,b,c,e,f   Tu, Jack V ^b,c,d   Ross, Joseph S ^g,h   Ko, Dennis T ^b,d   Carreon, Daniel ^a   Krumholz, Harlan M ^g,h  

^a WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

^b INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^e VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^f UNIVERSITY HEALTH NETWORK   (Canada)

^g YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h Robert Wood Johnson Clinical Scholars Program   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEZAFIBRATE; CLOFIBRATE; FENOFIBRATE; FENOFIBRIC ACID; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; GENERIC DRUG;

ARTICLE; CANADA; COHORT ANALYSIS; DRUG COST; DRUG USE; OBSERVATIONAL STUDY; POPULATION RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; UNITED STATES;

EID: 79952851918     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2011.353     Document Type: Article

References (35)

1. Brody H. Medicine's ethical responsibility for health care reform. N Engl J Med. 2010;362(4):283-285.
2. Redberg RF. Less is more. Arch Intern Med. 2010;170(7):584.
3. Fischer MA, Avorn J. Economic consequences of underuse of generic drugs. Health Serv Res. 2003;38(4):1051-1063.
4. ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563-1574.
5. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study) [published correction appears in Lancet. 2006;368:1415, 1420]. Lancet. 2005;366(9500):1849-1861.
6. Bloomberg Web site. Abbott sues Lupin, AMD, Apple, Time Warner, Zazzle: intellectual property. http://www.bloomberg.com/apps/news?pid= newsarchive&sid=a3qi6DC-WPeA. Accessed April 20, 2010.
7. Abourbih S, Filion KB, Joseph L, et al. Effect of fibrates on lipid profiles and cardiovascular outcomes. Am J Med. 2009;122(10):962-, e1-e8.
8. Jun M, Foote C, Lv J, et al. Effects of fibrates on cardiovascular outcomes. Lancet. 2010;375(9729):1875-1884.
9. US Food and Drug Administration. Approved drug products. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction= Search.Search-Drug-Name. Accessed March 27, 2010.
10. Health Canada. Notice of compliance. http://www.hc-sc.gc.ca/dhp-mps/ prodpharma/notices-avis/index-e.html. Accessed March 27, 2010.
11. Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA. 2004;292(21):2585-2590. (Pubitemid 39577514)
12. Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol. 2005;95(1):120-122. (Pubitemid 40051126)
13. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med. 1999;341(6):410-418. (Pubitemid 29362514)
14. Office of the Attorney General State of New York. Attorney General Cuomo announces settlement of antitrust suit against drug manufacturers. http://www.ag.ny.gov/media-center/2010/jan/jan7a-10.html. Accessed March 25, 2010.
15. Wall Street Journal Online. TriCor case may illuminate patent limits. http://online.wsj.com/article/SB121236509655436509.html?mod=2-1566-topbox. Accessed March 25, 2010.
16. IMS Health Inc. IMS data assets: data and information resources. http://www.imshealth.com/portal/site/imshealth/menuitem. a953aef4d73d1ecd88f611019418c22a/?vgnextoid= 63417ec23ff77110VgnVCM10000071812ca2RCRD&vgnextfmt=default. Accessed January 27, 2011.
17. Majumdar SR, McAlister FA, Soumerai SB. Synergy between publication and promotion. Am J Med. 2003;115(6):467-472.
18. Stafford RS, Furberg CD, Finkelstein SN, et al. Impact of clinical trial results on national trends in α-blocker prescribing, 1996-2002. JAMA. 2004;291(1):54-62.
19. Jackevicius CA, Tu JV, Ross JS, et al. Use of ezetimibe in the United States and Canada. N Engl J Med. 2008;358(17):1819-1828. (Pubitemid 351581194)
20. Jackevicius CA, Cox JL, Carreon D, et al. Long-term trends in use of and expenditures for cardiovascular medications in Canada. CMAJ. 2009;181:E19-E28.
21. Statistics Canada. 2001 Census of Canada. http://www12.statcan.ca/ english/census01/home/Index.cfm. Accessed April 3, 2010.
22. US Census Bureau. Table 1: population estimates. http://factfinder. census.gov/servlet/DTTable?-bm=y&-geo-id=01000US&-ds-name= PEP-2009-EST&-mt-name=PEP-2009-EST-G2009-T001. Accessed April 3, 2010.
23. Vachris MA, Thomas J. International price comparisons based on purchasing power parity. Month Labor Rev. 1999;October:3-12.
24. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med. 1987;317(20):1237-1245.
25. Alsheikh-Ali AA, Kuvin JT, Karas RH. Risk of adverse events with fibrates. Am J Cardiol. 2004;94(7):935-938. (Pubitemid 39349562)
26. Omar MA, Wilson JP. FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother. 2002;36(2):288-295. (Pubitemid 34126824)
27. Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med. 2002;346(7):539-540.
28. Backman JT, Kyrklund C, Kivistö KT, et al. Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther. 2000;68(2):122-129. (Pubitemid 30659167)
29. VHA Pharmacy Benefits Management. Statinfibrate report. http://www.pbm.va.gov/Safety%20Reports/87ry38statin-fibrate-Final.pdf. Accessed April 11, 2010.
30. Danzon PM, Furukawa MF. International prices and availability of pharmaceuticals in 2005. Health Aff (Millwood). 2008;27(1):221-233.
31. Office of the Attorney General State of California. TriCor settlement agreement. http://ag.ca.gov/cms-attachments/press/pdfs/n1844-tricor-settlement. pdf. Accessed March 24, 2010.
32. Orange Book Blog. Antitrust case against Abbott moves forward. http://www.orangebookblog.com/2006/05/antitrust-case-.html. Accessed March 24, 2010.
33. Institute of Medicine. Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease. Washington, DC: The National Academies Press; 2010.
34. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-2497.
35. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110(2):227-239. (Pubitemid 38924592)